Key result
Enhanced FcγR binding and antibody effector function were associated with protection from recurrent Staphylococcus aureus disease in a cohort of 319 children.
Why the study?
Staphylococcus aureus has no licensed vaccine and causes a high burden of recurrent infection, yet correlates of protection remain undefined.
What are the antibody correlates of resilience to Staphylococcus aureus disease and recurrence in children?
Cohort (n=319)
What are the antibody correlates of resilience to Staphylococcus aureus disease and recurrence in children?
The study identifies key antigen targets and functional antibody profiles associated with resilience to S. aureus disease, informing future vaccine and monoclonal antibody strategies.
Answers are grounded in this paper and cite their sources.
Large-scale pediatric S. aureus antibody profiling generates hypothesis-generating data; leaves open identification of protection correlates for future vaccines.
Staphylococcus aureus remains a major global pathogen with no licensed vaccine and high recurrent infection burden, yet correlates of protection remain undefined. In a prospective pediatric cohort, we profiled 319 children spanning non-carriers, asymptomatic carriers, those with skin and soft tissue infection (SSTI), or invasive disease. We interrogated 182,149 antibody features, generating the most comprehensive S. aureus immune profiling dataset to date. Antibody responses increased with age, marked by expansion of IgG subclasses and Fc-receptor engagement. Asymptomatic carriage was associated with functional antibody profiles targeting conserved surface antigens and select toxins. Multivariate modeling robustly distinguished clinical phenotypes and identified high-value antigens associated with disease resilience. Protection from recurrent disease converged on enhanced FcγR binding and antibody effector function. These findings nominate key antigen targets, and highlight anti-Hla neutralizing antibodies and functional antibodies to additional surface antigens that can be recapitulated through Fc engineering, informing next-generation vaccine and monoclonal antibody strategies.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) conducted a cohort in Staphylococcus aureus infection (n=319). Antibody profiles (FcγR binding and antibody effector function) vs. Different clinical phenotypes (non-carriers, asymptomatic carriers, SSTI, invasive disease) was evaluated on Clinical phenotypes and protection from recurrent disease. Enhanced FcγR binding and antibody effector function were associated with protection from recurrent Staphylococcus aureus disease in a cohort of 319 children.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: